CCR2/CCR5 dual inhibitor Cenicriviroc inhibits the recruitment of Ly6Chi monocytes, thereby improving histological damage and fibrosis in the NASH model [51]. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.